SG11201809471UA - Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof - Google Patents
Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereofInfo
- Publication number
- SG11201809471UA SG11201809471UA SG11201809471UA SG11201809471UA SG11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA SG 11201809471U A SG11201809471U A SG 11201809471UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- benzoimidazol
- diethylamino
- acrylamide
- butyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662330673P | 2016-05-02 | 2016-05-02 | |
PCT/US2017/030414 WO2017192451A1 (fr) | 2016-05-02 | 2017-05-01 | Formes polymorphes de 3-[2-butyl-1-(2-diéthylamino-ethyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide et leurs utilisations |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201809471UA true SG11201809471UA (en) | 2018-11-29 |
Family
ID=60203321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201809471UA SG11201809471UA (en) | 2016-05-02 | 2017-05-01 | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof |
Country Status (20)
Country | Link |
---|---|
US (2) | US10626092B2 (fr) |
EP (2) | EP3452035B1 (fr) |
JP (1) | JP2019514905A (fr) |
KR (1) | KR20190005904A (fr) |
CN (1) | CN109414425A (fr) |
AR (1) | AR108257A1 (fr) |
AU (1) | AU2017261218A1 (fr) |
BR (1) | BR112018072439A2 (fr) |
CA (1) | CA3022011A1 (fr) |
CL (1) | CL2018003109A1 (fr) |
CO (1) | CO2018012941A2 (fr) |
EA (1) | EA201892341A1 (fr) |
ES (1) | ES2886495T3 (fr) |
IL (1) | IL262578A (fr) |
MA (1) | MA44880A (fr) |
MX (1) | MX2018013349A (fr) |
PH (1) | PH12018502296A1 (fr) |
SG (1) | SG11201809471UA (fr) |
TW (1) | TW201741286A (fr) |
WO (1) | WO2017192451A1 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018157741A1 (fr) * | 2017-02-28 | 2018-09-07 | 苏州科睿思制药有限公司 | Formes cristallines d'un sel de sb-939, procédé de préparation associé et utilisation |
WO2019126282A1 (fr) | 2017-12-19 | 2019-06-27 | Assia Chemical Industries Ltd. | Polymorphes cristallins de pracinostat et de sels de pracinostat |
WO2019149262A1 (fr) * | 2018-02-05 | 2019-08-08 | 苏州科睿思制药有限公司 | Forme cristalline de sb-939, son procédé de préparation et son utilisation |
WO2021217180A1 (fr) * | 2020-04-22 | 2021-10-28 | Johnson Matthey Public Limited Company | Nouvelles formes de dichlorhydrate de pracinostat |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2291749A1 (fr) | 1974-11-20 | 1976-06-18 | Delalande Sa | Nouveaux benzimidazoles acetiques, leur procede de preparation et leur application en therapeutique |
AU668181B2 (en) | 1992-05-20 | 1996-04-26 | Merck & Co., Inc. | Ester derivatives of 4-aza-steroids |
SE9804212D0 (sv) | 1998-12-04 | 1998-12-04 | Astra Pharma Prod | Compounds |
ID30439A (id) | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
DE60006541D1 (de) | 1999-06-30 | 2003-12-18 | Merck & Co Inc | Src-kinase hemmende verbindungen |
EP1206260A4 (fr) | 1999-06-30 | 2002-10-30 | Merck & Co Inc | Composes inhibiteurs de la src kinase |
CA2378381A1 (fr) | 1999-07-16 | 2001-01-25 | Warner-Lambert Company | Traitement de douleurs chroniques au moyen d'inhibiteurs de mek |
KR20020015376A (ko) | 1999-07-16 | 2002-02-27 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | Mek 억제제를 사용한 만성 통증의 치료 방법 |
GB9919558D0 (en) | 1999-08-18 | 1999-10-20 | Hoechst Schering Agrevo Gmbh | Fungicidal compounds |
AU783504C (en) | 1999-11-23 | 2006-08-03 | Methylgene Inc. | Inhibitors of histone deacetylase |
TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
US6770666B2 (en) | 1999-12-27 | 2004-08-03 | Japan Tobacco Inc. | Fused-ring compounds and use thereof as drugs |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
US6642252B2 (en) | 2000-11-07 | 2003-11-04 | Bristol-Myers Squibb Company | Acid derivatives useful as serine protease inhibitors |
PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
CA2450555A1 (fr) | 2001-06-25 | 2003-01-03 | Merck & Co., Inc. | Composes d'heteroaryle fondus (pyrimidyle)(phenyle) substitues inhibiteurs de p38 et de la kinase pkg |
AR035543A1 (es) | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
US20040091951A1 (en) | 2002-02-07 | 2004-05-13 | Axys Pharmaceuticals, Inc. | Assay for measuring acetylation or deacetylation activity of an enzyme |
TW200406203A (en) | 2002-03-13 | 2004-05-01 | Array Biopharma Inc | N3 alkylated banzimidazole derivatives as MEK inhibitors |
PT2275102E (pt) | 2002-03-13 | 2015-10-27 | Array Biopharma Inc | Derivados de benzimidazole alquilado n3 como inibidores de mek |
AU2003231359B2 (en) | 2002-04-16 | 2009-04-30 | Teijin Limited | Piperidine derivatives having CCR3 antagonism |
DE10239042A1 (de) | 2002-08-21 | 2004-03-04 | Schering Ag | Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel |
WO2004078682A2 (fr) | 2003-03-05 | 2004-09-16 | Irm Llc | Composes cycliques et compositions servant d'inhibiteurs de proteines-kinases |
WO2004082638A2 (fr) | 2003-03-17 | 2004-09-30 | Syrrx, Inc. | Inhibiteurs d'histone deacetylase |
US7781595B2 (en) | 2003-09-22 | 2010-08-24 | S*Bio Pte Ltd. | Benzimidazole derivatives: preparation and pharmaceutical applications |
US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
US20050159470A1 (en) | 2003-12-19 | 2005-07-21 | Syrrx, Inc. | Histone deacetylase inhibitors |
WO2006101456A1 (fr) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Composes d'hydraxamate bicycliques contenant des heterocycles utiles en tant qu'inhibiteurs de l'histone desacetylase (hdac) |
CA2540459C (fr) * | 2005-09-08 | 2014-02-18 | S*Bio Pte Ltd | Composes de benzimidazole et utilisations dans le traitement des troubles de type proliferation |
TWI393708B (zh) | 2005-09-08 | 2013-04-21 | Mei Pharma Inc | 異羥肟酸脂化合物,其用途及其之合成方法 |
ES2703592T3 (es) * | 2007-03-07 | 2019-03-11 | Mei Pharma Inc | Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno |
EP2914254B1 (fr) * | 2012-10-30 | 2020-01-08 | MEI Pharma, Inc. | Polythérapies pour traiter des cancers chimiorésistants |
-
2017
- 2017-04-28 AR ARP170101104A patent/AR108257A1/es unknown
- 2017-05-01 SG SG11201809471UA patent/SG11201809471UA/en unknown
- 2017-05-01 CA CA3022011A patent/CA3022011A1/fr not_active Abandoned
- 2017-05-01 CN CN201780041511.XA patent/CN109414425A/zh active Pending
- 2017-05-01 MA MA044880A patent/MA44880A/fr unknown
- 2017-05-01 WO PCT/US2017/030414 patent/WO2017192451A1/fr unknown
- 2017-05-01 ES ES17793075T patent/ES2886495T3/es active Active
- 2017-05-01 BR BR112018072439-4A patent/BR112018072439A2/pt not_active IP Right Cessation
- 2017-05-01 AU AU2017261218A patent/AU2017261218A1/en not_active Abandoned
- 2017-05-01 KR KR1020187034681A patent/KR20190005904A/ko not_active IP Right Cessation
- 2017-05-01 JP JP2018555958A patent/JP2019514905A/ja active Pending
- 2017-05-01 MX MX2018013349A patent/MX2018013349A/es unknown
- 2017-05-01 EP EP17793075.7A patent/EP3452035B1/fr active Active
- 2017-05-01 EP EP21178272.7A patent/EP3939966A1/fr not_active Withdrawn
- 2017-05-01 US US16/098,435 patent/US10626092B2/en active Active
- 2017-05-01 EA EA201892341A patent/EA201892341A1/ru unknown
- 2017-05-02 TW TW106114551A patent/TW201741286A/zh unknown
-
2018
- 2018-10-24 IL IL262578A patent/IL262578A/en unknown
- 2018-10-29 PH PH12018502296A patent/PH12018502296A1/en unknown
- 2018-10-31 CL CL2018003109A patent/CL2018003109A1/es unknown
- 2018-11-29 CO CONC2018/0012941A patent/CO2018012941A2/es unknown
-
2020
- 2020-03-09 US US16/813,230 patent/US20200317621A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AR108257A1 (es) | 2018-08-01 |
EP3452035B1 (fr) | 2021-07-07 |
BR112018072439A2 (pt) | 2019-02-19 |
PH12018502296B1 (en) | 2019-07-08 |
AU2017261218A1 (en) | 2018-11-29 |
JP2019514905A (ja) | 2019-06-06 |
US20190152923A1 (en) | 2019-05-23 |
PH12018502296A1 (en) | 2019-07-08 |
IL262578A (en) | 2018-12-31 |
CN109414425A (zh) | 2019-03-01 |
ES2886495T3 (es) | 2021-12-20 |
US20200317621A1 (en) | 2020-10-08 |
TW201741286A (zh) | 2017-12-01 |
EP3452035A1 (fr) | 2019-03-13 |
WO2017192451A1 (fr) | 2017-11-09 |
CO2018012941A2 (es) | 2018-12-28 |
US10626092B2 (en) | 2020-04-21 |
MA44880A (fr) | 2021-03-17 |
EA201892341A1 (ru) | 2019-05-31 |
CA3022011A1 (fr) | 2017-11-09 |
EP3939966A1 (fr) | 2022-01-19 |
CL2018003109A1 (es) | 2019-04-26 |
KR20190005904A (ko) | 2019-01-16 |
EP3452035A4 (fr) | 2019-09-25 |
MX2018013349A (es) | 2019-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
SG11201909155VA (en) | Ask1 inhibitor compounds and uses thereof | |
SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
SG11201803627XA (en) | N-substituted indole derivatives as pge2 receptor modulators | |
SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201809471UA (en) | Polymorphic forms of 3-[2-butyl-1-(2-diethylamino-ehtyl)-1h-benzoimidazol-5-yl]-n-hydroxy-acrylamide and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201909807TA (en) | Methods of manufacturing of niraparib | |
SG11201903055UA (en) | Inhibitors of glucocorticoid receptor | |
SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
SG11201809162XA (en) | 6-aminopyridin-3-yl thiazoles as modulators of ror?t | |
SG11201901999XA (en) | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | |
SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease |